Everest Re Group, Ltd.
NYSE:EGInsurance - Reinsurance
-$0.22 today
- Market cap
- $15.56B
- Beta
- 0.30
- P/E (TTM)
- 6.7
- EPS (TTM)
- $50.49
- Dividend yield
- 2.37%
Volume 0.38M
Average 0.36M
EG Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Everest Re Group, Ltd.NYSE: EG
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development remains negative
Q2 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How EG compares with its peers on the latest reported figures
- EG's LTM Jun 2026 research & development of $0 is the highest of the 6 companies compared; the peer median is $0.
- Research & development amounts to 0.0% of revenue for EG, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding EG) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for EG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 11.33B | 11.99B | 14.46B | 17.08B | 17.32B |
| Cost of Revenue | 9.6B | 10.63B | 11.38B | 14.61B | 13.76B |
| Gross Profit | 1.73B | 1.36B | 3.09B | 2.47B | 3.55B |
| Gross Margin | 15.3% | 11.3% | 21.3% | 14.5% | 20.5% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 68M | 61M | 73M | 95M | 883.7M |
| Operating Expenses | 184M | 769M | 931M | 976M | 1.6B |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | 1.62B | 689M | 2.29B | 1.64B | 2.07B |
| EBITDA Margin | 14.3% | 5.7% | 15.8% | 9.6% | 11.9% |
| Operating Income | 1.54B | 588M | 2.15B | 1.5B | 1.95B |
| Operating Margin | 13.6% | 4.9% | 14.9% | 8.8% | 11.3% |
| Interest Income | 12M | 2M | 10M | 26M | 21M |
| Interest Expense | 70M | 101M | 134M | 149M | 139M |
| Other Income / Expenses | 2M | 0 | 0 | (2M) | (25M) |
| Income Before Tax | 1.55B | 588M | 2.15B | 1.49B | 1.93B |
| Pre-Tax Margin | 13.6% | 4.9% | 14.9% | 8.7% | 11.1% |
| Income Tax Expense | 167M | (9M) | (363M) | 120M | 339M |
| Net Income | 1.38B | 597M | 2.52B | 1.37B | 1.59B |
| Net Margin | 12.2% | 5.0% | 17.4% | 8.0% | 9.2% |
| EPS (Basic) | 34.66 | 15.19 | 60.19 | 31.78 | 37.86 |
| EPS (Diluted) | 34.62 | 15.19 | 60.24 | 31.78 | 37.86 |
| Weighted Avg Shares | 39.26M | 39M | 41.3M | 42.7M | 41.41M |
| Weighted Avg Shares (Diluted) | 39.3M | 39M | 41.3M | 42.7M | 41.41M |
Everest Re Group, Ltd.
NYSE:EG
Intrinsic Alpha fair value
Locked
Current Price
$420.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.